# A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

Study · id `cardio:ct-nct02998840` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02998840](<https://clinicaltrials.gov/study/NCT02998840>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02998840

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.

## Technical summary

Registry record NCT02998840. Randomized; double masking; primary purpose treatment. Start 2016-11 (actual); primary completion 2017-04-25 (actual). Results posted on 2022-08-15.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 132 participants (enrolled count; ClinicalTrials.gov record NCT02998840, source copy `cardio:ctgov-nct02998840-2022-09-15`, retrieved 2026-10-26)
- Started: 2016-11 (actual) (ClinicalTrials.gov record NCT02998840, source copy `cardio:ctgov-nct02998840-2022-09-15`, retrieved 2026-10-26)
- Primary completion: 2017-04-25 (actual) (ClinicalTrials.gov record NCT02998840, source copy `cardio:ctgov-nct02998840-2022-09-15`, retrieved 2026-10-26)
- Completion: 2017-06-26 (actual) (ClinicalTrials.gov record NCT02998840, source copy `cardio:ctgov-nct02998840-2022-09-15`, retrieved 2026-10-26)
- Results first posted: 2022-08-15 (ClinicalTrials.gov record NCT02998840, source copy `cardio:ctgov-nct02998840-2022-09-15`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02998840, source copy `cardio:ctgov-nct02998840-2022-09-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02998840-2022-09-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure
- Condition: Prehypertension
- Condition: Hypertension, Stage I
- Intervention (Biological): B244
- Intervention (Biological): Vehicle
- Lead sponsor: AOBiome LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Veristat, Inc.
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: a90544208db956e5ac39f11c8cb955b263554ff5c2ead093dbe7479d64ac115c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
